Orlando Health Ventures
VC Fund
Orlando Health Ventures is a VC fund focused on Health Care and Medical Device. Orlando Health Strategic Innovations will bring to life ideas, concepts and inventions from our team members and physicians.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Orlando Health Ventures invests in
Health CareMedical DeviceMedicalBiotechnologyBiopharma
Stages Orlando Health Ventures invests in
Series BSeries CVenture - Series UnknownSeries DFunding Round
Countries Orlando Health Ventures invests in
United StatesUnited Kingdom
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Bobby Helmedag
|
|||
David Strong
|
|||
3 more contacts available
Investment Focus
Industry
- Health Care 9 (64%)
- Medical Device 7 (50%)
- Medical 5 (36%)
- Biotechnology 4 (29%)
- Biopharma 2 (14%)
Stage
- Series B 5 (36%)
- Series C 3 (21%)
- Venture - Series Unknown 2 (14%)
- Series D 1 (7%)
- Funding Round 1 (7%)
Country
- United States 9 (64%)
- United Kingdom 1 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Bobby Helmedag
Managing Director
|
Managing Director | Total investments: 5 | Find email | |
|
David Strong
President & CEO
|
President & CEO | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
410 Medical
|
410 Medical has developed a simple, intuitive solution that allows a single healthcare provider to rapidly deliver fluid to critically ill patients, improving care, and saving lives. Their device allows fast set-up, improves resuscitation speed, minimizes provider fatigue, and frees providers to address other patient care issues simultaneously.This solution is particularly useful in pre-hospital settings and the emergency department and where speed is critical and resources may be limited.It was founded in 2013 and headquartered in Durham, North Carolina. | $12M / Venture - Series Unknown / Jul 14, 2026 | |
|
410 Medical
|
410 Medical has developed a simple, intuitive solution that allows a single healthcare provider to rapidly deliver fluid to critically ill patients, improving care, and saving lives. Their device allows fast set-up, improves resuscitation speed, minimizes provider fatigue, and frees providers to address other patient care issues simultaneously.This solution is particularly useful in pre-hospital settings and the emergency department and where speed is critical and resources may be limited.It was founded in 2013 and headquartered in Durham, North Carolina. | $14M / Series B / Mar 17, 2025 | |
Francis Medical
|
Francis Medical is a medical technology company developing therapeutic solutions to treat prostate, kidney, and bladder cancer. Francis Medical is developing a device for treating prostate cancer, the second most common cancer in American men, using a new platform to treat endourological cancers, water vapor technology. The thermal energy stored insterile water vapor is used to treat cancerous tissue via a simple transurethral procedure, potentially minimizing life-altering side effects. | $80M / Series C / Jan 07, 2025 | |
G.I. Windows
|
G.I. Windows is a clinical-stage company developing the first fundamental breakthrough in surgical anastomotic technology. This technology will allow less invasive surgery and offer the capability of developing more procedures new to the world. The company is creating a new category in healthcare designed to create less invasive surgery and reducehealthcare costs.G.I. Windows is committed to innovation that helps improve the way diagnostic and interventional procedures impact the essential balance between both patients and the healthcare system. It was founded in 2012 and is headquartered in West Bridgewater, Massachusetts, United States. | $37M / Nov 20, 2024 | |
|
G.I. Windows
|
G.I. Windows is a clinical-stage company developing the first fundamental breakthrough in surgical anastomotic technology. This technology will allow less invasive surgery and offer the capability of developing more procedures new to the world. The company is creating a new category in healthcare designed to create less invasive surgery and reducehealthcare costs.G.I. Windows is committed to innovation that helps improve the way diagnostic and interventional procedures impact the essential balance between both patients and the healthcare system. It was founded in 2012 and is headquartered in West Bridgewater, Massachusetts, United States. | $37M / Series B / Nov 20, 2024 | |
Endogenex
|
Endogenex develops an endoscopic procedure to help patients with type 2 diabetes regain control of their blood glucose levels. Established in 2017, Endogenex has developed a novel therapy that utilizes pulsed electric fields to promote regeneration of the duodenal mucosa for improvement in glycemic control in patients with T2D. | $88M / Series C / Jun 25, 2024 | |
Arrivo BioVentures LLC
|
Our expertise is drug development. Whether we are developing a reformulated product, a new chemical entity, or a biologic, the team at Arrivo BioVentures has expertise in identifying regulatory strategies to expedite the path to approval and the efficient implementation of the clinical programs themselves. We coordinate with the FDA (and otherregulatory bodies) early and often to gain agreement on the development programs for our products, minimizing surprises and speeding implementation. | $45.3M / Series B / Nov 29, 2023 | |
|
410 Medical
|
410 Medical has developed a simple, intuitive solution that allows a single healthcare provider to rapidly deliver fluid to critically ill patients, improving care, and saving lives. Their device allows fast set-up, improves resuscitation speed, minimizes provider fatigue, and frees providers to address other patient care issues simultaneously.This solution is particularly useful in pre-hospital settings and the emergency department and where speed is critical and resources may be limited.It was founded in 2013 and headquartered in Durham, North Carolina. | $7.5M / Series B / May 25, 2023 | |
Sensydia
|
Developer of a portable, point-of-care hemodynamic measurement platform that uses proprietary sensor technology and machine learning to guide critical patient management decisions in heart failure, sepsis, pulmonary hypertension, and other critical diseases. The Sensydia Cardiac Performance System™ (CPS) is entirely non-invasive, trained to goldstandard, and can be deployed in minutes in the hospital, clinic, office or at home. By making hemodynamic insights as accessible as routine blood pressure readings, CPS will enable early disease detection and improve disease management through accurate, easy-to-use, non-invasive monitoring. | $8M / Venture - Series Unknown / May 09, 2023 | |
|
410 Medical
|
410 Medical has developed a simple, intuitive solution that allows a single healthcare provider to rapidly deliver fluid to critically ill patients, improving care, and saving lives. Their device allows fast set-up, improves resuscitation speed, minimizes provider fatigue, and frees providers to address other patient care issues simultaneously.This solution is particularly useful in pre-hospital settings and the emergency department and where speed is critical and resources may be limited.It was founded in 2013 and headquartered in Durham, North Carolina. | $6.3M / Series B / Nov 10, 2022 | |
| See all 14 investments → | |||
Co-Investors
Rex Health Ventures
7 deals together
Hatteras Venture Partners
5 deals together
OSF Healthcare System
3 deals together
Solas BioVentures
3 deals together
WakeMed Health & Hospitals
3 deals together
Ballad Ventures
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Medical Device Investors
11,047 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
FAQ
What does Orlando Health Ventures invest in?
Orlando Health Ventures invests primarily in Health Care, Medical Device and Medical startups, most often at Series B and Series C stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Orlando Health Ventures?
Public channels for Orlando Health Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Orlando Health Ventures?
The team at Orlando Health Ventures includes Bobby Helmedag (Managing Director) and David Strong (President & CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
